$10.0M
+$10.0M this year1 filing since 2026 · latest Equity filed
RenovoRx, Inc. is a publicly traded (Nasdaq: RNXT) life sciences company in Mountain View, California developing targeted oncology therapies and commercializing drug-delivery hardware. Its patented Trans-Arterial Micro-Perfusion (TAMP) platform delivers therapeutic agents across the arterial wall near a tumor site rather than systemically. The company sells RenovoCath, an FDA-cleared drug-delivery device for temporary vessel occlusion and chemotherapeutic infusion, and is running the Phase III TIGeR-PaC trial of intra-arterial gemcitabine in locally advanced pancreatic cancer. CEO Shaun Bagai has led the company since 2014.
What sets it apart
Delivers chemotherapy directly to the tumor site through the arterial wall instead of intravenously, aiming to improve local drug concentration while reducing the systemic toxicity that limits conventional infusion.
An FDA-cleared drug-delivery device for temporary vessel occlusion and infusion of chemotherapeutic agents, used to deliver treatment directly to solid tumors.
